{"name":"Carmot Therapeutics, Inc.","slug":"carmot-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CT-868","genericName":"CT-868","slug":"ct-868","indication":"Other","status":"phase_2"},{"name":"CT-388","genericName":"CT-388","slug":"ct-388","indication":"Other","status":"phase_2"},{"name":"Placebo as SC Injection","genericName":"Placebo as SC Injection","slug":"placebo-as-sc-injection","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"CT-868","genericName":"CT-868","slug":"ct-868","phase":"phase_2","mechanism":"CT-868 is a selective inhibitor of a molecular target being developed for metabolic or inflammatory disease.","indications":[],"catalyst":""},{"name":"CT-388","genericName":"CT-388","slug":"ct-388","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo as SC Injection","genericName":"Placebo as SC Injection","slug":"placebo-as-sc-injection","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOTWRKUFFxSkZqdnVqMGlXaEVwaWtLV0dJc21RU2tqeGZpSzhhbEplcWFNUG8zVlk4OE9UVW56VmY0NmJkYjJTTTE0M3oxNlhteE1pNk1IQXhzZzVmTTZYNkVFR2tXMmlDdl84c1c5RHBSQU4wTDFhNzlCVDY5SldIcTBreHg0NnlRR0E0Q0hNM2xMRU43bXMwS0lkbGRKSzhHY2pWVkw2T29zd2w5TEItSW1uQjE5ejVOcmdZNWRQOTZfeFZyUEZucG9jZlZUMk9DMkhacVVPVngyU19ia04tUV9KZTZjM2duUldRN1Yzb2NraTB3VW5mbm9odEpJSEZxS2NvOWlZLThzaTRaWF9uZE9IRmVXd0d2YXVmRUhIOEtIaVItOVJzSGF6M0hDY3dENVhDODQzMzZ6U1BkWWlOdDM5Q2U?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barcha","headline":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma Astra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPcDNodk45amQxOG1XZ0V3d05fLVBiY3dmX0Vsb19DT3BQa3pHNGkzdnpuM3JhZXdEZGdIVlJSVDJhNjh4N25GZzg3dVdFTlZ0dmE2UGxQOUZ1T3N1NnNUNXpXSXN1TnA1NXBBc2lpeVdxQzVFaVh2SDhpRzBDeFctYUlSS0RMQl9SdXlDRDlyUkY4NlE?oc=5","date":"2026-01-29","type":"pipeline","source":"BioSpace","summary":"Roche Plans To Go Toe-to-Toe With Novo, Lilly in Obesity - BioSpace","headline":"Roche Plans To Go Toe-to-Toe With Novo, Lilly in Obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPcTFBMDlPOTJiZ0t5QjNQUDJyNEdGa0w4VGEwd0NLTjM0akdBWXcwaHdkUGU5UnZ3MmdVSDk5Wm43bU5tTktJLTRiQmFoSmNEcDJta3NfZTZXVXR4SE1PVEhUOVc3dXVwMHZRRUlqakRmXzdaMkFuZk5NTTRRekJWbjBHbmlqcW1Nb2JGOE1kVQ?oc=5","date":"2026-01-06","type":"deal","source":"Fierce Biotech","summary":"In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech","headline":"In Structure licensing deal, Roche commits $100M to shore up GLP-1 position","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOLXNlQWNNSEFqYWtER3FEenBtRy1fMjF5eHJ0UGdLM05lZTVObG9WUmNkWEpFdmQxU2FEVjkxRDFHd3NZNXB3VFI5cGVWYWRSM2EtQ2R3Q1VDODVCTXBRdlpWWV9pY29ad1pxOGFGNTVSZVExeVdqLTQ3dERVMkhaWHhqYlpKa29FWEN2QkVNX3U3Mnd5OEFSLU1XTUlIODRTMjlZWQ?oc=5","date":"2025-09-22","type":"pipeline","source":"Fierce Biotech","summary":"'We have the will': Roche unveils strategy to become 'top 3' obesity company - Fierce Biotech","headline":"'We have the will': Roche unveils strategy to become 'top 3' obesity company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOc0YxVldvMElPbUxzdXVsck5Iem5raDB0SUVpODBSQ0hMVExJc1IydHFSZHUzYjlFVVV1YjdYX1ROMUxmbFdoRnkwczB3NVktbHBQam82Y3lGTkNVTl9LRW9Pd2lUcmlIQ2Q2YjEyb0xIMFpNYnVVNXBCMGJDY2dhSWt4M0pUaVVEa2kwekhTdi12QUhkVGI0WWR1RmM?oc=5","date":"2025-07-24","type":"pipeline","source":"Fierce Biotech","summary":"Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out - Fierce Biotech","headline":"Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPVWl4V2xTeHE3ZW9NbDY3Y0MtOFdyMWh2M1M0RlNCTC1TUXhkVWEwWmtYbkxxNDAtX0ljTERwUnduaDZlR1VhTXRFdldJbS1tMTVWXzU3S3RfQ2xhRE1PWVN1TTNjVFNZSWlUZ2VZVTJxQXp1YWhsN0Yyb3BTRHdvNXZwVUdpS2lSSXBmVWJvNE5tRkZYalhGVWFoWi1oek9fT21PeDRMSVFMemZxalNZbG9CX1R6N1NLa0NTOFJHdUNQTU52?oc=5","date":"2024-09-30","type":"pipeline","source":"Reuters","summary":"Roche targets more than $3 billion in annual obesity sales - Reuters","headline":"Roche targets more than $3 billion in annual obesity sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNd205bTF4WTVzNmFMYVk3aXdteW5vZEtaSEhXaXRJTmNBMmgyWHllOG5EbWRRRWx5YXJ0M2VjZjk3cWhTaFpKT0M2bHNIUHN0R3h0all5MHVvU2NJa1hDSnQtS3F2MGZDZGtSZ0hMSk5fNjFaNEwyWlkwTDVUQXQzZmhiT2dmWmEzNUpDaUJCZHlWMDAzR2pmb01jcFJWbW1uWUE?oc=5","date":"2024-07-29","type":"pipeline","source":"Contract Pharma","summary":"Roche Completes $2.7B Acquisition of Carmot Therapeutics - Contract Pharma","headline":"Roche Completes $2.7B Acquisition of Carmot Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxORy1pTGwwMlo2UzlTU19zdU1FZWotOWtVeXhjb1JOV21FamJ0UmVRZVNseW1CVjM1LVYyc2xyQWJkZ3owQWpBbVozcGRIVldFU0g5U2RtbXk3WlpFUk5PdktSVDM0bXpQamlFYjI3ckN2UG9CNUJwUE11N19qV24wc0kwa1RsdmZw?oc=5","date":"2023-12-04","type":"deal","source":"BioPharma Dive","summary":"Roche joins obesity drug chase with $2.7B deal for startup Carmot - BioPharma Dive","headline":"Roche joins obesity drug chase with $2.7B deal for startup Carmot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQaHUtRmpudmRWRmtQVjJQcWJGcEJBQlU0cUlieTNnRkZNYW1XU3JidmtXRXpJNnNxTWh4a2kzeEtpcElsOEs3eE9Oc0Vpa3NsM2QxckpCa1RCUkRpeG82QXJLS3ZVd2UwT191TVBqR0FieUJBOXlIcnlJejF3V3l4aWVoTGsyVjFneUdobQ?oc=5","date":"2023-12-04","type":"deal","source":"Pharmaceutical Technology","summary":"Roche agrees to acquire Carmot Therapeutics for $2.7bn - Pharmaceutical Technology","headline":"Roche agrees to acquire Carmot Therapeutics for $2.7bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE95XzBMRG13cklpQ3JHaGJVczAwT0NvRWpWZmE5czBkUmY0eDVVSTFrSV9LTEMtcE1reGZjeENHQVNHODY2UWRBa1V4TUhyRDZ2d0pNZ2FxSWJKQlVEWEJSVDFBSkdEbkp6U2plLTdPV21rX2pvQ3ZLbWhB?oc=5","date":"2023-12-04","type":"deal","source":"statnews.com","summary":"Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion - statnews.com","headline":"Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNcG1FT3VGbi1laWFSZExrQ2lQTkxqRFUyZGJzYjJVYWxlSjluVFhxZlBrd250N3JsQnVpQVdvanRoWWItWHMxd2JYY3FhUmRDVkR5TkFxRzlDY1JLUUVpYTFnQ0prWG8xbHVLaGxLdG5nUTVSOWFGQWhMSG40azRWd0cwRlU3Z1FyWUpHMjRn0gGTAUFVX3lxTFA5NWw3LVR3eG5XeS03TGRuQ2ZEWWNyQ1RGX09nQkFMY3lXZURrMXdEUTd2UWVvazZDSWhLNTctZmlfNFcwUVRKME1ZYTBlbGdvaVpHUThyYXNRaTk4aGxKZldoSzFyX3lDSzJNbmJnZnZsRkp6WThvTmlORmRadWIzVlJaTzNSUEs2eEREWHptZzNFTQ?oc=5","date":"2023-12-04","type":"pipeline","source":"CNBC","summary":"Roche enters obesity market with Carmot takeover but drugs may not be available until 2030 - CNBC","headline":"Roche enters obesity market with Carmot takeover but drugs may not be available until 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxONmZBV2tmZzFDMGg4YjRoMUNGUF9mT0V2VHJZMHd0MVRCdUVCbVFtamlWVmNkZFdQUXlrOU1TT25laWx3ajl6ZGpCUHV5bnpTMUhORmtNLUtDeEpzNFlPVVdpTWJwZGlvZkY1VmcyMkViRnpycGprM09HVlRSWXNLM1A1TGFiOEtzQXdBSF9qcUhZREt6SXEyRWRNTGFBTjJsR3VPVDZMLWh2UEpJYmpRSmZMdzZaUDg?oc=5","date":"2023-12-04","type":"pipeline","source":"Pharmaceutical Executive","summary":"Roche Bolsters Obesity, Diabetes R&D Portfolio With Acquisition of Carmot Therapeutics - Pharmaceutical Executive","headline":"Roche Bolsters Obesity, Diabetes R&D Portfolio With Acquisition of Carmot Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}